Department of Human Genetics, Medical School, Saarland University, 66421 Homburg, Germany.
Wilms Tumor (WT) is the most common renal childhood tumor. Recently, we reported a cDNA microarray expression pattern that varied between WTs with different risk histology. Since the Societé Internationale d'Oncologie Pédiatrique (SIOP) in Europe initiates treatment without a histological confirmation, it is important to identify blood-born markers that indicate WT development. In a multicenter study, we established an autoantibody signature by using an array with 1,827 recombinant E. coli clones. This array was screened with sera of patients with WT recruited by SIOP or the Children's Oncology Group (COG). We report an extended number of antigens that are reactive with autoantibodies present in sera from patients with WT. We established an autoantibody signature that separates untreated patients with WT recruited in SIOP from non-WT controls with a specificity of 0.83 and a sensitivity of 0.82 at standard deviations of 0.02 and 0.04, respectively. Likewise, patients recruited in the COG in the United States were separated from the controls with an accuracy of 0.83 at a standard deviation of 0.02. Proteins that were most significant include zinc finger proteins (e.g., ZFP 346), ribosomal proteins and the protein fascin that has been associated with various types of cancer including renal cell carcinoma. Our study provides first evidence for autoantibody signatures for WTs and suggests that these may be most informative before chemotherapy. We present the first multicenter study of autoantibody signatures in patients with WT. We established an autoantibody signature that separates patients with WT from controls.
Written by:
Schmitt J, Heisel S, Keller A, Leidinger P, Ludwig N, Habel N, Furtwängler R, Nourkami-Tutdibi N, Wegert J, Grundy P, Gessler M, Graf N, Lenhof HP, Meese E. Are you the author?
Reference: Int J Cancer. 2011 Sep 12. Epub ahead of print.
doi: 10.1002/ijc.26419
PubMed Abstract
PMID: 21913182
UroToday.com Renal Cancer Section
